A Unified Mechanistic Framework for Modeling Short- and Long-Acting siRNAs: Impact of RISC Stability on PD Durability

Model-Informed Strategies for GLP-1 RA Development: Linking PKPD to Weight Loss and Glycemic Control

Predicting Phase3 efficacy of combination therapy in Ulcerative Colitis #IBD

From Xenograft to Clinic: QSP-guided dosing and step-up strategy for CD3×HLA-G T Cell Engagers TCE

Clinical Efficacy and cytokine release syndrome (CRS) risk of CD3 Bispecifics in prostate cancer

Epithelial Barrier

Leveraging in vitro data from novel drug candidates to prioritize antibody combinations in autoimmune disease using a QSP model of IBD

QSP model to predict clinical PK/PD of siRNA therapeutics and learnings from model development

QSP Platform for Predicting Alternate Priming Dose, Efficacy, and CRS Incidence in CD3 Bispecifics for STEAP1 Prostate Cancer

A quantitative systems pharmacology (QSP) model framework for combined clinical efficacy and hematological toxicity predictions for antibody-drug conjugates

DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING ALTERNATE PRIMING DOSE

A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications